Cat. No. 2430
Chemical Name: N-[4-[2(R)-Amino-3-mercaptopropyl]a
Biological ActivityCAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor. Strongly inhibits the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras (IC50 values are 3 and > 10 μM respectively). Causes G0-G1 cell cycle block and apoptosis in A549 cells and inhibits cell invasion and migration in COLO 320CM cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Porcu et al (2010) A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics. Mol.Cancer 9 197. PMID: 20653956.
Kusama et al (2003) Selective inhibition of cancer cell invasion by a geranylgeranyltransferase inhibitor. Clin.Exp.Meta. 20 561.
Miquel et al (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-227 causes G2-M enrichment in A549 cells. Cancer Res. 57 1846. PMID: 9157972.
McGuire et al (1996) Platelet-derived growth factor receptor tyrosine kinase phosphorylation requires protein geranylgeranylation but not farnesylation. J.Biol.Chem. 271 27402. PMID: 8910319.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GGTI 298 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GGTI 298, supplier, GGTI298, geranylgeranyltransferase, GGTase1, Tocris Bioscience, Protein Prenyltransferase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitorP-3FAX-Neu5Ac
Sialic acid analog; sialyltransferase inhibitorTolcapone
COMT inhibitor; also inhibits transthyretin aggregationJNJ DGAT2-A
DGAT2 inhibitorLLY 507
Potent SMYD2 inhibitor
November 12 - 16, 2016
San Diego, CA, USA